


Newron and Myung In Pharm join hands to improve schizophrenia treatment in South Korea

10 January 2025 | News

Myung In Pharm to develop, manufacture and commercialise evenamide in South Korea



Italy headquartered Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous system, and Myung In Pharm Co., South Korea's leading CNS specialist pharmaceutical company, have entered into a license agreement to develop, manufacture and commercialise Newron's innovative modulator of the excessive release of glutamate, evenamide, an add-on therapy for treatment-resistant schizophrenia (TRS) and poorly responding patients with schizophrenia, in South Korea.

Under the terms of the license agreement, Myung In Pharm will contribute 10% of the total patient population to be enrolled into Newron's upcoming pivotal Phase III trial and cover the costs related to this population. Myung In Pharm's involvement leverages its established clinical infrastructure and expertise in the central nervous system (CNS) field.

Furthermore, the company will bear a percentage of eligible global development costs and will also be responsible for all regulatory, registration, marketing, and commercialization costs for evenamide in South Korea. In return, Newron will receive an upfront payment, milestone payments for development and regulatory achievements, and royalties on net sales. Further details were not disclosed by the parties.

The Phase III randomised, double-blind, one-year trial is expected to begin in H1 2025 and will compare evenamide to placebo as an add-on treatment in at least 600 patients with TRS. It will be coordinated by Newron, who will oversee the trial design, execution, and data analysis. Myung In Pharm will be responsible for enrolling patients in South Korea through its extensive network of clinical sites, as well as providing support with monitoring and data collection. Newron continues to pursue further development opportunities for evenamide in other territories.